About our research labs
Dr. Ash’s research is focused on both understanding the cause of blindness due to retinal degeneration and developing therapies to prevent loss of sight.
The Dinculesu Lab focuses on developing therapeutic approaches for Usher syndrome type 3, an autosomal recessive disorder, which leads to progressive retinal degeneration and hearing loss.
Dr Hauswirth has a long-term interest in the delivery and testing of potentially therapeutic genes for Dominant, Recessive and X-Linked Retinitis Pigmentosa, Leber Congenital Amaurosis, Achromatopsia, Blue Cone Monochromacy, Usher’s Disease, Macular Degeneration, Diabetic Retinopathy, Glaucoma and Optic Neuropathies in natural and transgenic animal models of each human disease.
Our research goal is to understand the pathogenesis of diabetic retinopathy and to develop more effective therapies for treatment of this condition, with a particular focus on the targeting ocular renin angiotensin system.
Dr. Lobanova pioneered the concept of proteasomal overload as a common pathobiological factor shared between multiple forms of retinal degeneration. Building on these findings, she is developing novel approaches to manipulate proteasomal activity, which could be used in clinics to treat retinal diseases in a mutation-independent manner.
The principal focus of the Smith laboratory is on the molecular biochemistry and cell biology of the eye, with particular emphasis on the retina. The Smith Lab research has centered on canonical and non-canonical signaling pathways in photoreceptors, particularly focusing on the ancillary cascades signaled by the phototransduction elements.